Aquestive Therapeutics
AQST
185 hedge funds and large institutions have $300M invested in Aquestive Therapeutics in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 69 increasing their positions, 44 reducing their positions, and 18 closing their positions.
284% more call options, than puts
Call options by funds: $8.26M | Put options by funds: $2.15M
57% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 44
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
3% more funds holding
Funds holding: 180 → 185 (+5)
0% more capital invested
Capital invested by funds: $299M → $300M (+$941K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.51% less ownership
Funds ownership: 58.91% → 57.4% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$4.05M |
| 2 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$3.08M |
| 3 |
BlackRock
New York
|
+$2.36M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.14M |
| 5 |
Renaissance Technologies
New York
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.07M |
| 2 |
Morgan Stanley
New York
|
-$3.93M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.1M |
| 4 |
Jane Street
New York
|
-$2.49M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.84M |
AQST Hedge Fund Activity: Q2 2026 in Review
185 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2026, worth a combined $300M — up 0.32% from $299M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AQST positions and 18 closed out — a net gain of 6 holders — while 69 added to existing stakes and 44 trimmed.
The largest buyer was Nuveen, adding an estimated $4.05M. The largest seller was Balyasny Asset Management, cutting an estimated $9.07M.
- 185 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2026, up from 180 in Q1 2026.
- Funds reported $300M of Aquestive Therapeutics stock for Q2 2026, up 0.32% quarter-over-quarter.
- 24 funds opened new Aquestive Therapeutics positions in Q2 2026 and 18 closed out, a net change of +6 holders.
- The largest Aquestive Therapeutics buyer in Q2 2026 was Nuveen, an estimated $4.05M added.
- The largest Aquestive Therapeutics seller in Q2 2026 was Balyasny Asset Management, an estimated $9.07M sold.
Based on aggregated 13F filings for Q2 2026.